- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07711418
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis (ZENITH AD-2)
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin (NKTR-358) Monotherapy in the Treatment of Patients ≥ 12 Years of Age With Moderate-to- Severe Atopic Dermatitis
This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as compared to placebo.
The estimated participant overall duration is approximately 15 months.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: Nektar Recruitment
- Telefonnummer: 855-482-8676
- E-post: StudyInquiry@nektar.com
Studieorter
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35203
- Rekrytering
- Nektar Investigative Site
-
-
California
-
Oxnard, California, Förenta staterna, 93030
- Rekrytering
- Nektar Investigative Site
-
Palmdale, California, Förenta staterna, 93551
- Rekrytering
- Nektar Investigative Site
-
Sacramento, California, Förenta staterna, 95815
- Rekrytering
- Nektar Investigative Site
-
-
Florida
-
Tamarac, Florida, Förenta staterna, 33321
- Rekrytering
- Nektar Investigative Site
-
-
Georgia
-
Savannah, Georgia, Förenta staterna, 31406
- Rekrytering
- Nektar Investigative Site
-
-
Louisiana
-
Metairie, Louisiana, Förenta staterna, 70006
- Rekrytering
- Nektar Investigative Site
-
-
Missouri
-
Kirksville, Missouri, Förenta staterna, 63501
- Rekrytering
- Nektar Investigative Site
-
Lee's Summit, Missouri, Förenta staterna, 64064
- Rekrytering
- Nektar Investigative Site
-
-
Nevada
-
Las Vegas, Nevada, Förenta staterna, 89144
- Rekrytering
- Nektar Investigative Site
-
-
New Jersey
-
Robbinsville, New Jersey, Förenta staterna, 08691
- Rekrytering
- Nektar Investigative Site
-
-
New York
-
The Bronx, New York, Förenta staterna, 10455
- Rekrytering
- Nektar Investigative Site
-
-
Ohio
-
Columbus, Ohio, Förenta staterna, 43213
- Rekrytering
- Nektar Investigative Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Male or female patients, ≥ 12 years of age on the day of signing the informed consent form and weighing ≥ 40 kg prior to randomization at Baseline
Chronic atopic dermatitis (AD) defined as onset of AD signs and symptoms
≥ 12 months prior to Screening as determined by the Investigator through patient interview and/or review of medical history at the Screening Visit
- Patients must meet the following AD severity criteria:
- IGA score ≥ 3 (scale of 0 to 4) at Screening and Baseline
- ≥ 10.0% of BSA involvement at Screening and Baseline
- EASI ≥ 16.0 at Screening and Baseline
- Are candidates for systemic therapy and have history, documented by a physician and/or the Investigator, of inadequate response to existing topical medications within 6 months preceding Screening, or history of intolerance to a topical therapy
- Provide written, informed consent to participate in the study and follow the study procedures, including compliance with the use of highly effective contraceptives
Exclusion Criteria:
- Are currently experiencing or have a history of concomitant skin conditions other than AD, including skin infection in the area affected by the patient's AD that requires treatment with systemic antimicrobial therapy
- Are currently experiencing or have a history of unstable course of AD
- History of chronic idiopathic urticaria at any time or urticaria from other causes within 4 weeks prior to randomization at the Baseline Visit.
- Have a history of TCS use suggestive of a high risk for topical corticosteroid (TCS) withdrawal
- Have received any of the following treatments at any time before Screening: aldesleukin; investigational IL-2 analog; systemic biologic; oral JAKi; or any prior investigational agent for AD
- Have a current or recent acute, active infection
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Blinded Induction Period: Rezpegaldesleukin every 2 weeks
Rezpegaldesleukin every 2 weeks during the induction period
|
Läkemedelsform: Injektionslösning Administreringssätt: subkutant
Andra namn:
|
|
Placebo-jämförare: Blinded Induction Period: Placebo
Placebo every 2 weeks during the induction period
|
Läkemedelsform: Injektionslösning Administreringssätt: subkutant
|
|
Experimentell: Blinded Maintenance Period: Rezpegaldesleukin every 4 weeks
Rezpegaldesleukin every 4 weeks during the maintenance period
|
Läkemedelsform: Injektionslösning Administreringssätt: subkutant
Andra namn:
|
|
Experimentell: Blinded Maintenance Period: Rezpegaldesleukin every 12 weeks
Rezpegaldesleukin every 12 weeks during the maintenance period
|
Läkemedelsform: Injektionslösning Administreringssätt: subkutant
Andra namn:
|
|
Placebo-jämförare: Blinded Maintenance Period: Placebo
Placebo every 4 weeks during the maintenance period
|
Läkemedelsform: Injektionslösning Administreringssätt: subkutant
|
|
Experimentell: Open-Label Escape
Rezpegaldesleukin at a frequency determined by the investigator during the open-label escape
|
Läkemedelsform: Injektionslösning Administreringssätt: subkutant
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
US only: Number of participants with an Investigator's Global Assessment (IGA) score of 0 or 1 and reduction ≥ 2 points from baseline at Week 24
Tidsram: Week 0 and Week 24
|
The IGA scale ranges from 0 to 4, with higher score indicating more severe disease.
|
Week 0 and Week 24
|
|
Non-US regions only: Number of participants with an Investigator's Global Assessment (IGA) score of 0 or 1 at Week 24
Tidsram: Week 0 and Week 24
|
The IGA scale ranges from 0 to 4, with higher score indicating more severe disease.
|
Week 0 and Week 24
|
|
Non-US regions only: Number of participants with a ≥ 75% reduction in Eczema Area and Severity Index (EASI) score from baseline at Week 24 (EASI-75)
Tidsram: Week 0 and Week 24
|
The EASI scores range from 0 to 72, with higher scores indicating more severe atopic dermatitis.
|
Week 0 and Week 24
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
US only: Number of participants with a ≥ 75% reduction in EASI score from baseline at Week 24 (EASI-75)
Tidsram: Week 0 and Week 24
|
The EASI scores range from 0 to 72, with higher scores indicating more severe atopic dermatitis.
|
Week 0 and Week 24
|
|
Number of participants with a ≥ 90% reduction in EASI score from baseline at Week 24 (EASI-90)
Tidsram: Week 0 and Week 24
|
The EASI scores range from 0 to 72, with higher scores indicating more severe atopic dermatitis.
|
Week 0 and Week 24
|
|
Number of participants at week 6 achieving a 4-point or greater improvement in Itch numerical rating scale (NRS) in the subset of participants with a 4-point or greater Itch NRS at baseline
Tidsram: Week 0 and Week 6
|
The itch NRS goes from 0 to 10, with higher score indicating more severe itch.
|
Week 0 and Week 6
|
|
Number of participants at week 24 achieving a 4-point or greater improvement in Itch numerical rating scale (NRS) in the subset of participants with a 4-point or greater Itch NRS at baseline
Tidsram: Week 0 and Week 24
|
The itch NRS goes from 0 to 10, with higher score indicating more severe itch.
|
Week 0 and Week 24
|
|
Number of participants at week 6 achieving a 4-point or greater improvement in Skin Pain numerical rating scale (NRS) in the subset of participants with a 4-point or greater Skin Pain NRS at baseline
Tidsram: Week 0 and Week 6
|
The Skin Pain NRS goes from 0 to 10, with higher score indicating more severe pain.
|
Week 0 and Week 6
|
|
Number of participants at week 24 achieving a 4-point or greater improvement in Skin Pain numerical rating scale (NRS) in the subset of participants with a 4-point or greater Skin Pain NRS at baseline
Tidsram: Week 0 and Week 24
|
The Skin Pain NRS goes from 0 to 10, with higher score indicating more severe pain.
|
Week 0 and Week 24
|
|
Number of participants at week 6 achieving a 1.25-point or greater improvement in Atopic Dermatitis Sleep Scale Question 1 (ADSS Q1) in the subset of participants with a 1.25-point or greater ADSS Q1 at baseline
Tidsram: Week 0 and Week 6
|
The ADSS Q1 goes from 0 to 4, with higher score indicating more difficulty sleeping.
|
Week 0 and Week 6
|
|
Number of participants at week 24 achieving a 1.25-point or greater improvement in ADSS Q1 in the subset of participants with a 1.25-point or greater ADSS Q1 at baseline
Tidsram: Week 0 and Week 24
|
The ADSS Q1 goes from 0 to 4, with higher score indicating more difficulty sleeping.
|
Week 0 and Week 24
|
|
Change in Asthma Control Questionnaire-5 (ACQ-5) score from baseline at Week 24 in the subpopulation of patients with a 0.5-point or greater ACQ-5 at baseline
Tidsram: Week 0 and Week 24
|
The ACQ-5 goes from 0 to 6, with higher score indicating worse asthma control.
|
Week 0 and Week 24
|
|
Number of participants at week 24 achieving a 0.5-point or greater improvement in ACQ-5 in the subset of participants with a 0.5-point or greater ACQ-5 at baseline
Tidsram: Week 0 and Week 24
|
The ACQ-5 goes from 0 to 6, with higher score indicating worse asthma control.
|
Week 0 and Week 24
|
|
Change in Sino-Nasal Outcome Test (SNOT-22) score from baseline at Week 24 in the subpopulation of patients with an 8.9-point or greater SNOT-22 at baseline
Tidsram: Week 0 and Week 24
|
The SNOT-22 scores range from 0 to 110, with a higher score indicating more severe symptoms
|
Week 0 and Week 24
|
|
Number of participants at Week 24 achieving a 8.9-point or greater reduction from baseline in SNOT-22 in the subpopulation of patients with an 8.9-point or greater SNOT-22 at baseline
Tidsram: Week 0 and Week 24
|
The SNOT-22 scores range from 0 to 110, with a higher score indicating more severe symptoms
|
Week 0 and Week 24
|
|
Number of participants at week 24 achieving an Adapted Investigator's Global Assessment (aIGA) response of 0 or 1
Tidsram: Week 0 and Week 24
|
The aIGA scale ranges from 0 to 1, with a lower score indicating improvement in atopic dermatitis.
|
Week 0 and Week 24
|
|
Number of participants with treatment emergent adverse events (TEAEs)
Tidsram: Through participant study completion, approximately Week 56
|
Through participant study completion, approximately Week 56
|
|
|
Number of participants with treatment emergent serious adverse events
Tidsram: Through participant study completion, approximately Week 56
|
Through participant study completion, approximately Week 56
|
|
|
Number of participants with treatment related serious adverse events
Tidsram: Through participant study completion, approximately Week 56
|
Through participant study completion, approximately Week 56
|
|
|
Number of participants with treatment emergent adverse events of special interest
Tidsram: Through participant study completion, approximately Week 56
|
Through participant study completion, approximately Week 56
|
|
|
Number of participants with treatment related adverse events of special interest
Tidsram: Through participant study completion, approximately Week 56
|
Through participant study completion, approximately Week 56
|
|
|
Number of participants with TEAEs leading to treatment discontinuation
Tidsram: Through participant study completion, approximately Week 56
|
Through participant study completion, approximately Week 56
|
|
|
Number of participants with TEAEs leading to dose hold
Tidsram: Through participant study completion, approximately Week 56
|
Through participant study completion, approximately Week 56
|
|
|
Number of participants with TEAEs leading to dose modifications
Tidsram: Through participant study completion, approximately Week 56
|
Through participant study completion, approximately Week 56
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Study Director, Nektar Therapeutics
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- 25-358-10
- 2025 (U.S.S. NIH-anslag/kontrakt: Faculty of Social Sciences Scientific Grant at the University of Gdańsk)
- 2025-525129-11-00 (Ctis)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .